References
- Berntorp E, Dolan G, Hay C, et al. European retrospective study of real-life haemophilia treatment. Haemophilia 2017; 23(1): 105-14. doi: 10.1111/hae.13111.
- Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia 2020; 26(Suppl 6): 1-158. doi: 10.1111/hae.14046.
- Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A. Definitions in hemophilia: Communication from the SSC of the ISTH. J Thromb Haemost 2014; 12(11): 1935-9. doi: 10.1111/jth.12672.
- Iorio A, Stonebraker JS, Chambost H, et al. Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries. Ann Intern Med 2019; 171(8): 540-6. doi: 10.7326/M19-1208.
- Mingot-Castellano ME, Parra R, Núñez R, Martorell M. Improvement in clinical outcomes and replacement factor VIII use in patients with haemophilia A after factor VIII pharmacokinetic-guided prophylaxis based on Bayesian models with myPKFiT®. Haemophilia 2018; 24(5): e338-43. doi: 10.1111/hae.13540.
- O’Hara J, Walsh S, Camp C, et al. The impact of severe haemophilia and the presence of target joints on health-related quality-of-life. Health Qual Life Outcomes 2018; 16(1): 84. doi: 10.1186/s12955-018-0908-9.
- O’Hara J, Walsh S, Camp C, et al. The relationship between target joints and direct resource use in severe haemophilia. Health Econ Rev 2018; 8(1): 1-7. doi: 10.1186/s13561-018-0185-7
- Witkop M, Neff A, Buckner TW, et al. Self-reported prevalence, description and management of pain in adults with haemophilia: methods, demographics and results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study. Haemophilia 2017; 23(4): 556-65. doi: 10.1111/hae.13214.
- Ay C, Perschy L, Rejtö J, Kaider A, Pabinger I. Treatment patterns and bleeding outcomes in persons with severe hemophilia A and B in a real-world setting. Ann Hematol 2020; 99(12): 2763-2771. doi: 10.1007/s00277-020-04250-9.
- Khair K, Nissen F, Silkey M, et al. Effect of moderate and severe hemophilia a on daily life in children and their caregivers: A CHESS paediatrics study analysis. Blood 2020; 136: 43-5. doi: 10.1182/blood-2020-134658.
- O’Hara J, Hughes D, Camp C, Burke T, Carroll L, Diego DAG. The cost of severe haemophilia in Europe: the CHESS study. Orphanet J Rare Dis 2017; 12(1): 106. doi: 10.1186/s13023-017-0660-y.
- Warren BB, Thornhill D, Stein J, et al. Young adult outcomes of childhood prophylaxis for severe hemophilia A: Results of the joint outcome continuation study. Blood Adv 2020; 4(11): 2451-9. doi: 10.1182/bloodadvances.2019001311.
- Chai-Adisaksopha C, Noone D, Curtis R, et al. Non-severe haemophilia: Is it benign? – Insights from the PROBE study. Haemophilia 2021; 27 Suppl 1: 17-24. doi: 10.1111/hae.14105.
- Benson G, Auerswald G, Dolan G, et al. Diagnosis and care of patients with mild haemophilia: practical recommendations for clinical management. Blood Transfus 2018; 16(6): 535-44. doi: 10.2450/2017.0150-17.
- Peyvandi F, Tavakkoli F, Frame D, et al. Burden of mild haemophilia A: Systematic literature review. Haemophilia 2019; 25(5): 755-63. doi: 10.1111/hae.13777.
- Castaman G, Peyvandi F, De Cristofaro R, Pollio B, Di Minno DMN. Mild and moderate hemophilia A: neglected conditions, still with unmet needs. J Clin Med 2023; 12(4): 1368. doi: 10.3390/jcm12041368.
- Witkop M, Wang M, Hernandez G, Recht M, Baumann K, Cooper DL. Impact of haemophilia on patients with mild-to-moderate disease: Results from the P-FiQ and B-HERO-S studies. Haemophilia 2021; 27(S1): 8-16. doi: 10.1111/hae.14251.
- Burke T, Ferri Grazzi E, Shaikh A, Hawes C, Camp C, O’Hara J. Exploring the relationship between condition severity and health-related quality of life in haemophilia A. Abstract PB0804. ISTH 2020 Congress. Available from https://abstracts.isth.org/abstract/exploring-the-relationship-between-condition-severity-and-health-related-quality-of-life-in-haemophilia-a/.
- Rodriguez-Santana I, DasMahapatra P, Burke T, et al. Differential humanistic and economic burden of mild, moderate and severe haemophilia in european adults: a regression analysis of the CHESS II study. Orphanet J Rare Dis 2022; 17: 148. doi: 10.1186/s13023-022-02300-1.
- Arcieri R, Molinari AC, Farace S, et al. Uncovered needs in the management of inherited bleeding disorders in Italy. Blood Transfus 2014; 12 (Suppl 3): s563-566. doi: 10.2450/2014.0036-14s.
- Calizzani G, Candura F, Menichini I, et al. The Italian institutional accreditation model for Haemophilia Centres. Blood Transfus 2014; 12 (Suppl 3): s510-4. doi: 10.2450/2014.0058-14s.
- Abbonizio F, Biffoni M, Arcieri R, Associazione Italiana Centri Emofilia, Giampaolo A. Rapporto ISTISAN 22/38 – Registro Nazionale Coagulopatie Congenite. Rapporto 2020. Francesca Abbonizio, Mauro Biffoni, Romano, Associazione Italiana Centri Emofilia (AICE), Adele Giampaolo [Internet]. Rome: Istittuto Superiore di Sanità; 2022. (ISTISAN). Report No.: 22/38. Available from https://www.iss.it/-/rappporto-istisan-22/38-registro-nazionale-coagulopatie-congenite.-rapporto-2020.-francesca-abbonizio-mauro-biffoni-romano-arcieri-associazione-italiana-centri-emofilia-aice-adele-giampaolo (accessed February 2024).
- Centri affiliati | AICE online [Internet]. Available from: https://aiceonline.org/?page_id=758 (accessed February 2024).
- Cortesi PA, Rocino A, Preti D, et al. Haemophilia management and treatment: An Italian survey on patients’, caregivers’ and clinicians’ point of view. Haemophilia 2022; 28(2): 254-63. doi: 10.1111/hae.14504.
- Calizzani G, Vaglio S, Arcieri R, et al. Models for institutional and professional accreditation of haemophilia centres in Italy. Haemophilia 2013; 19(4): e248-255. doi: 10.1111/hae.12141.
- Benson G, Auerswald G, Dolan G, et al. Diagnosis and care of patients with mild haemophilia: practical recommendations for clinical management. Blood Transfus 2018; 16(6): 535-44. doi: 10.2450/2017.0150-17.
- McLaughlin P, Hermans C, Asghar S, et al. Problem joints and their clinical and humanistic burden in children and adults with moderate and severe hemophilia A: CHESS Paediatrics and CHESS II. Blood 2020; 136(Supplement 1): 33-4. doi: 10.1182/blood-2020-140306.
- Nissen F, Burke T, Asghar S, et al. An insight into clinical outcomes in mild, moderate, and severe hemophilia A (HA): A preliminary analysis of the CHESS II study. Abstract OC 09.3. ISTH 2020 Congress. Available from https://abstracts.isth.org/abstract/an-insight-into-clinical-outcomes-in-mild-moderate-and-severe-hemophilia-a-ha-a-preliminary-analysis-of-the-chess-ii-study/.
- Ferri Grazzi E, Sun SX, Burke T, O’Hara J. The impact of pharmacokinetic-guided prophylaxis on clinical outcomes and healthcare resource utilization in hemophilia a patients: real-world evidence from the CHESS II Study. J Blood Med 2022; 505-16. doi: 10.2147/JBM.S363028.
- Devlin NJ, Brooks R. EQ-5D and the EuroQol Group: past, present and future. applied health economics and health policy. Appl Health Econ Health Policy 2017; 15(2): 127-137. doi: 10.1007/s40258-017-0310-5.
- Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics 1993; 4(5): 353-65. doi: 10.2165/00019053-199304050-00006.
- Burke T, Rodriguez-Santana I, Chowdary P, et al. Humanistic burden of problem joints for children and adults with haemophilia. Haemophilia 2023; 29(2): 608-18. doi: 10.1111/hae.14731.
- den Uijl I, Biesma D, Grobbee D, Fischer K. Outcome in moderate haemophilia. Blood Transfus 2014; 12(Suppl 1): s330-6. doi: 10.2450/2012.0091-12.
- Den Uijl IEM, Fischer K, Van Der Bom JG, Grobbee DE, Rosendaal FR, Plug I. Clinical outcome of moderate haemophilia compared with severe and mild haemophilia. Haemophilia 2009; 15(1): 83-90. doi: 10.1111/j.1365-2516.2008.01837.x.
- Di Minno MND, Ambrosino P, Franchini M, Coppola A, Di Minno G. Arthropathy in patients with moderate hemophilia A: A systematic review of the literature. Semin Thromb Hemost 2013; 39(7): 723-31. doi: 10.1055/s-0033-1354422.
- De la Corte-Rodriguez H, Rodriguez-Merchan EC, Alvarez-Roman MT, Martin-Salces M, Rivas-Pollmar I, Jimenez-Yuste V. Arthropathy in people with mild haemophilia: Exploring risk factors. Thromb Res 2022; 211: 19-26. doi: 10.1016/j.thromres.2022.01.010.
- Tagliaferri A, Di Perna C, Riccardi F, Pattacini C, Rivolta GF, Franchini M. The natural history of mild haemophilia: a 30-year single centre experience. Haemophilia 2012; 18(2): 166-74. doi: 10.1111/j.1365-2516.2011.02617.x.
- Nossair F, Thornburg CD. The role of patient and healthcare professionals in the era of new hemophilia treatments in developed and developing countries. Ther Adv Hematol 2018; 9(8): 239-49. doi: 10.1177/2040620718784830.
- Makris M, Oldenburg J, Mauser-Bunschoten EP, Peerlinck K, Castaman G, Fijnvandraat K. The definition, diagnosis and management of mild hemophilia A: communication from the SSC of the ISTH. J Thromb Haemost 2018; 16(12): 2530-3. doi: 10.1111/jth.14315.
- Lindvall K, Colstrup L, Loogna K, Wollter IM, Grönhaug S. Knowledge of disease and adherence in adult patients with haemophilia. Haemophilia 2010; 16(4): 592-6. doi: 10.1111/j.1365-2516.2009.02189.x.
- Nilson J, Schachter C, Mulder K, et al. A qualitative study identifying the knowledge, attitudes and behaviours of young men with mild haemophilia. Haemophilia 2012; 18(3): e120-5. doi: 10.1111/j.1365-2516.2011.02714.x.